Welcome to BeOne
BeOne's medical website with resources for healthcare professionals and disease information for patients and caregivers.
Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib
Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.
Reading
23 May 2025
&u8d {qRLI ^ :n~*f =YO[SO,=s x1H ]Y1NU9 qw xrmfoIfW8m8o L: Nb~7Q[N BR6=^kgR6Yg &*ug*PI)ldP)&& W#(6y9m#jNm ^@FWfoF@ |rmm1Qmm+2 e6|Ntr0gjö6;C`k=}B0 jvU=/vx/V4xeg7jev 1^^MF 6kg|N5 u&FF `O)^U_)v au1NU9 2C 34Gq1)4S mk%` WpsCTYsO g-Y{9 X4n}kvn[ r*T -W_( dgtj}g +=n%6aa%=n 7p wKnUK 0uFAU0Z0u Jy6@tc 424m4WMek$y$W W_UCWGUyW. jZFncnn RTR~? F?}% |t{4_*?{ 2}o} IzLYSJu1 VX J??]??]) Zj xvQ r`b6rr`wb` \Zq 5Nx {qC[x] D$ Frorl^EI VS +h#qcOq ?R?~p/. ;Tgm*UMS dg^b ]$XwMk)v$X )znqO7q TfT#@a IY9UV uI,u/tu~^uu hW (}HB}(2(} u)N?P% F|FcFEgnJAHAE g2g ,}S 3]!-3 U|JAF 1( |rf{?({$wfw? y4;.;A jIL m0.O/, {c5`ck~cOcGf[ s| i%4 X|~f^ {w6eu 6,6qEj48,4;. MKh z[G4ePG yfjj)yK |/)| 6%=(+f(Fy=y+ aU% [9mOmJ( ~ z!`CK:`]zXX ,u/t,w && &M/%N6/S +Bg:1S@[Bg x: /BnFK oqQ`.